Skip to main content Skip to section navigation Skip to footer
Capricor Therapeutics, Inc.
  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors (DMD)
  • Our Science
    • Deramiocel (Biologic Medicine)
    • Exosomes Technology
    • Publications
    • Strategic Partnerships
  • Pipeline
    • Pipeline
    • Duchenne Muscular Dystrophy Overview
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Latest Proxy Statement and Annual Report
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
Oct 11, 2024 9:15 am EDT

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Oct 09, 2024 9:15 am EDT

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Oct 04, 2024 9:15 am EDT

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Sep 24, 2024 8:00 am EDT

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Sep 23, 2024 9:25 am EDT

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

Sep 17, 2024 9:15 am EDT

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Sep 06, 2024 8:30 am EDT

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Aug 07, 2024 4:05 pm EDT

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 31, 2024 9:00 am EDT

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

Jul 01, 2024 9:00 am EDT

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Visit us on Linkedin
  • Visit us on Facebook
  • Visit us on Instagram
  • Visit us on Twitter
©2025 Capricor Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences